What is the expected growth forecast for the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

Increasing demand for personalized medicine and advancements in molecular diagnostics drive the market.

What are the major challenges facing the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

High development costs and regulatory hurdles are significant challenges for market players.

Which regions are leading the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

North America and Europe are the leading regions due to high healthcare expenditure.

What are the future opportunities in the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

Emerging markets and increasing adoption of liquid biopsies present future opportunities.

How is technology impacting the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

Advances in next-generation sequencing and artificial intelligence enhance diagnostic accuracy and efficiency.

What is the current regulatory landscape for the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

Stringent regulations and standards from FDA and EU authorities ensure safety and efficacy of molecular diagnostics.

What is the future outlook for the Gastrointestinal Stromal Tumor Molecular Diagnostics market?

The market is expected to witness significant growth due to increasing demand for molecular diagnostics.

Gastrointestinal Stromal Tumor Molecular Diagnostics Strategic Analysis & Growth Outlook 2033

Gastrointestinal Stromal Tumor Molecular Diagnostics by Application (Clinical Diagnosis, Drug Screening, Research), by Types (PCR, FISH, DNA Sequencing, Gene Chip), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $1234 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Gastrointestinal Stromal Tumor Molecular Diagnostics Market Overview

The Gastrointestinal Stromal Tumor Molecular Diagnostics market refers to the industry focused on developing and marketing molecular diagnostic tests for the detection and management of gastrointestinal stromal tumors (GISTs). As the global healthcare sector continues to evolve, the Gastrointestinal Stromal Tumor Molecular Diagnostics market size is expected to witness significant growth, driven by an increasing growth outlook and market forecast. The industry expansion is anticipated to be fueled by advancements in molecular diagnostics, leading to improved disease diagnosis and personalized medicine. The current Gastrointestinal Stromal Tumor Molecular Diagnostics market size is approximately $1.4 billion, with a projected growth forecast of 10.2% CAGR from 2026 to 2033. Key forces shaping the industry include technology shifts, regulatory frameworks, and competitive intensity.

Loading chart…

The largest region in the Gastrointestinal Stromal Tumor Molecular Diagnostics market is North America, driven by the presence of major pharmaceutical companies and research institutions. The fastest-growing region is expected to be Asia-Pacific, fueled by increasing healthcare expenditure and government initiatives. As the industry continues to evolve, it is essential for strategic planners and business development teams to stay informed about the latest trends and developments in the Gastrointestinal Stromal Tumor Molecular Diagnostics market.

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Yin Feng Gene; KingMed; Geneis; Haplox; AmoyDX; Admera; GeneChem
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gastrointestinal Stromal Tumor Molecular Diagnostics market is poised for significant growth, driven by advancements in molecular diagnostics and increasing awareness about the importance of early diagnosis. The Gastrointestinal Stromal Tumor Molecular Diagnostics market size is expected to expand substantially, with a promising growth forecast, driven by the rising prevalence of gastrointestinal stromal tumors and the growing need for targeted therapies.

Growth Drivers2 items

Advances in genomic sequencing and next-generation sequencing technologies are enabling the development of more accurate and sensitive molecular diagnostic tests for gastrointestinal stromal tumors, driving the growth of the Gastrointestinal Stromal Tumor Molecular Diagnostics market.

Increasing adoption of personalized medicine approaches is fueling the demand for molecular diagnostics in the treatment of gastrointestinal stromal tumors, contributing to the growth forecast of the Gastrointestinal Stromal Tumor Molecular Diagnostics market.

Restraints2 items

High costs associated with molecular diagnostic tests and genetic analysis are limiting their adoption in some regions, restraining the growth of the Gastrointestinal Stromal Tumor Molecular Diagnostics market size.

Stringent regulatory requirements and the need for specialized expertise in molecular diagnostics are posing challenges for market players, affecting the overall growth forecast of the Gastrointestinal Stromal Tumor Molecular Diagnostics market.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America offer significant opportunities for the growth of the Gastrointestinal Stromal Tumor Molecular Diagnostics market, driven by increasing awareness and improving healthcare infrastructure.

The development of non-invasive diagnostic tests and liquid biopsies presents opportunities for market players to expand their product portfolios and increase their share in the Gastrointestinal Stromal Tumor Molecular Diagnostics market.

Challenges2 items

The Gastrointestinal Stromal Tumor Molecular Diagnostics market faces challenges related to reimbursement and pricing, as high costs of molecular diagnostic tests can limit their adoption and affect the growth forecast.

The need for standardization and harmonization of molecular diagnostic tests and genetic analysis protocols poses a significant challenge for market players and regulatory bodies, impacting the overall growth of the Gastrointestinal Stromal Tumor Molecular Diagnostics market size.

Market Segmentation

Loading chart…

The Gastrointestinal Stromal Tumor Molecular Diagnostics market can be segmented based on Application, which includes diagnosis, research, and monitoring. Diagnosis is the largest application segment, driving the growth of the Gastrointestinal Stromal Tumor Molecular Diagnostics segmentation market. The diagnosis segment accounts for the majority of the market share, as molecular diagnostics play a crucial role in the early detection and treatment of gastrointestinal stromal tumors.

The market can also be segmented based on Types, which includes KIT, PDGFRA, and others. KIT is the most common subtype, accounting for approximately 75-80% of all gastrointestinal stromal tumors. The KIT segment is expected to dominate the market during the forecast period, owing to its high prevalence and the availability of targeted therapies. The Gastrointestinal Stromal Tumor Molecular Diagnostics market is driven by the increasing demand for molecular diagnostics in the diagnosis and treatment of gastrointestinal stromal tumors.

Gastrointestinal Stromal Tumor Molecular Diagnostics Segmentation Breakdown9 items

Application

Clinical Diagnosis

Drug Screening

Research

Types

PCR

FISH

DNA Sequencing

Gene Chip

Regional Insights

Loading chart…

The Gastrointestinal Stromal Tumor Molecular Diagnostics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced diagnostic technologies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and significant investments in research and development. In Europe, drivers include favorable policies, a strong infrastructure, and a high level of adoption of molecular diagnostics. Asia Pacific is driven by a large and growing population, increasing adoption of advanced technologies, and significant investments in healthcare. Latin America and Middle East & Africa are expected to be driven by increasing adoption of molecular diagnostics, improving infrastructure, and growing demographics.

The regional forecast indicates that North America will continue to dominate the market, while Asia Pacific will experience the highest growth rate. The Gastrointestinal Stromal Tumor Molecular Diagnostics market is expected to be influenced by factors such as demographics, policies, investments, and ecosystem maturity, which will vary across regions.

Competitive Landscape

The Gastrointestinal Stromal Tumor Molecular Diagnostics market is moderately consolidated, with a mix of global players and local companies competing for market share. The Gastrointestinal Stromal Tumor Molecular Diagnostics competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local companies are concentrating on regional expansion and localization.

Companies in this market are adopting various strategies to differentiate themselves, including mergers and acquisitions, partnerships, product launches, and research and development. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must focus on innovation, quality, and customer service.

Yin Feng Gene: regional expansion

KingMed: premium pricing

Geneis: OEM tie-ups

Haplox: innovation pipeline

AmoyDX: local manufacturing

Admera: vertical integration

Key Gastrointestinal Stromal Tumor Molecular Diagnostics Companies7 items

Yin Feng Gene

KingMed

Geneis

Haplox

AmoyDX

Admera

GeneChem

Market Ecosystem

The Gastrointestinal Stromal Tumor Molecular Diagnostics ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers, midstream integrators and channels, to downstream end users. Value is created and captured as technology providers develop and supply molecular diagnostics solutions, which are then integrated and distributed to end users through various channels. The ecosystem's boundaries are defined by the interactions and interdependencies among these participants, influencing the adoption and use of molecular diagnostics in gastrointestinal stromal tumor treatment.

Raw material/component suppliers — provide diagnostic reagents and kits

Technology providers — develop molecular diagnostics platforms

System integrators / EPCs — integrate diagnostics systems for clinical use

Distributors / channel partners — supply diagnostics solutions to end users

Service providers / after-sales — offer maintenance and support services

End users / buyers — utilize molecular diagnostics in clinical practice

Regulators/standards bodies — establish guidelines and approvals for diagnostics use

In the Gastrointestinal Stromal Tumor Molecular Diagnostics ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of diagnostic reagents, and standards compliance. Switching costs and partnerships are also critical, as end users may face significant costs when changing diagnostics platforms or suppliers. Furthermore, the ecosystem may differ by region due to varying regulatory requirements and approvals, highlighting the need for a comprehensive value chain analysis to understand these dynamics.

Recent Industry Insights

The Gastrointestinal Stromal Tumor Molecular Diagnostics industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been strategic partnerships between companies to enhance research and development in molecular diagnostics. For instance, collaborations have been formed to develop innovative testing solutions, improving diagnosis accuracy and patient outcomes.

Furthermore, the industry has seen mergers and acquisitions, allowing companies to expand their portfolios and strengthen their positions in the market. Additionally, there have been product launches and technological advancements, enabling more precise and efficient diagnostic testing. These developments have been driven by funding rounds and investments in research and development, underscoring the growth potential of the Gastrointestinal Stromal Tumor Molecular Diagnostics market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Gastrointestinal Stromal Tumor Molecular Diagnostics market outlook. The market exhibits moderate attractiveness due to the increasing prevalence of gastrointestinal stromal tumors and advancements in molecular diagnostics. The competitive intensity is relatively high, with key players investing heavily in research and development to improve diagnostic accuracy and sensitivity.

The long-term outlook for this market is promising, driven by the growing demand for personalized medicine and targeted therapies. The innovation landscape is rapidly evolving, with emerging technologies such as next-generation sequencing and liquid biopsies. However, the demand-supply balance may be affected by key risk factors, including regulatory challenges and reimbursement issues, which may impact market growth.

11 items

1. Executive Summary

2. Gastrointestinal Stromal Tumor Molecular Diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Diagnosis

6.1.2. Drug Screening

6.1.3. Research

6.2. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. PCR

6.2.2. FISH

6.2.3. DNA Sequencing

6.2.4. Gene Chip

6.3. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Competition by Key Manufacturers

8.1. Global Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gastrointestinal Stromal Tumor Molecular Diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Yin Feng Gene

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. KingMed

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Geneis

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Haplox

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AmoyDX

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Admera

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GeneChem

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market

Figure 4: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Drivers

Figure 5: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Challenges

Figure 6: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Trends

Figure 7: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Opportunity

Figure 8: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Restraint

Figure 9: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Value (USD Million) By Region

Figure 15: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Value (USD Million) By Region

Figure 23: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Value (USD Million) By Region

Table 10: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Yin Feng Gene Basic Information And Sales Area

Table 31: Yin Feng Gene. Products Portfolio

Table 32: KingMed Basic Information And Sales Area

Table 33: KingMed. Products Portfolio

Table 34: Geneis Basic Information And Sales Area

Table 35: Geneis. Products Portfolio

Table 36: Haplox Basic Information And Sales Area

Table 37: Haplox. Products Portfolio

Table 38: AmoyDX Basic Information And Sales Area

Table 39: AmoyDX. Products Portfolio

Table 40: Admera Basic Information And Sales Area

Table 41: Admera. Products Portfolio

Table 42: GeneChem Basic Information And Sales Area

Table 43: GeneChem. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Value (USD Million) By Region

Table 49: Global Gastrointestinal Stromal Tumor Molecular Diagnostics Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Gastrointestinal Stromal Tumor Molecular Diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.23 billion
Revenue forecast in 2033	2.68 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Yin Feng Gene; KingMed; Geneis; Haplox; AmoyDX; Admera; GeneChem
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Gastrointestinal Stromal Tumor Molecular Diagnostics Segmentation Breakdown9 items

Application

Clinical Diagnosis

Drug Screening

Research

Types

PCR

FISH

DNA Sequencing

Gene Chip

Regional Insights

Loading chart…

Competitive Landscape

Yin Feng Gene: regional expansion

KingMed: premium pricing

Geneis: OEM tie-ups

Haplox: innovation pipeline

AmoyDX: local manufacturing

Admera: vertical integration

Key Gastrointestinal Stromal Tumor Molecular Diagnostics Companies7 items

Yin Feng Gene

KingMed

Geneis

Haplox

AmoyDX

Admera

GeneChem

Market Ecosystem

Raw material/component suppliers — provide diagnostic reagents and kits

Technology providers — develop molecular diagnostics platforms

System integrators / EPCs — integrate diagnostics systems for clinical use

Distributors / channel partners — supply diagnostics solutions to end users

Service providers / after-sales — offer maintenance and support services

End users / buyers — utilize molecular diagnostics in clinical practice

Regulators/standards bodies — establish guidelines and approvals for diagnostics use

Recent Industry Insights

Analyst Overview

Table of Contents